In Three-Way Merger, Acuity Will Go Public, Secures Credit Line to Help Develop AMD Rx | GenomeWeb
Acuity Pharmaceuticals this week joined the ranks of other publicly traded RNAi drug developers through a deal that includes merging with two other firms.
 
According to Philadelphia-based Acuity, it has merged with Froptix, a privately held developer of treatments for eye diseases located in Gainesville, Fla., and eXegenics, a public company formerly developing cancer and infectious disease therapies, but which currently has no active operations.
 

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

In PLOS this week: genetic study of breast cancer in Egyptian families, mutations linked to cleft lip and palate, and more.

Council Bluffs, Iowa, schools are encouraging more girls to pursue STEM courses, according to the Associated Press.

Because of new open-access requirements, Gates Foundation-funded researchers can't publish in some top journals, Nature News reports.

In Science this week: deletion of one microRNA allows pluripotent stem cells to form embryonic and non-embryonic lineages, and more.